secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001171843-26-003156
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q1 net loss $23M; fast track for HBV drug; Amoytop license $25M upfront
------------------------------------------------------------------------------

- Fast Track Designation from FDA for pevifoscorvir sodium for chronic HBV infection.
- Phase 2 B-SUPREME interim analysis: DSMB recommended increasing HBeAg- sample size to 100; futility criteria not met.
- Exclusive license with Amoytop for Greater China: $25M upfront, up to $420M milestones plus tiered royalties.
- Cash, equivalents, investments $54.9M at March 31, 2026 (Dec 31, 2025: $77.8M); expected to fund into Q4 2026 inclusive of $25M upfront.
- Net loss Q1 2026: $23.0M ($2.21/share) vs net income $43.1M ($5.12/share) in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184326003156/0001171843-26-003156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184326003156/f8k_050726.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer